BFRA Biofrontera AG

16.09
-6.81  -30%
Previous Close 22.9
Open 19.55
52 Week Low 5.27
52 Week High 55
Market Cap $360,813,133
Shares 22,424,682
Float 22,424,682
Enterprise Value $230,774,328
Volume 1,275,129
Av. Daily Volume 158,979
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Ameluz
Basal cell carcinoma
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Ameluz
Actinic keratosis
Phase 3
Phase 3
Phase 3 data met primary endpoint - March 20, 2019. Additional trials required with patient recruitment to commence 2H 2020.
Ameluz
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase 3
Phase 3
Phase 3 planned.
Ameluz
Acne
Phase 3
Phase 3
Phase 3 planned.

Latest News

  1. Leverkusen, Germany, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (GREY:BFFTF) announced on July 27, 2020 the issuance of the 1.00% qualified subordinated mandatory convertible bond 2020/2021 with pre-emptive subscription rights for shareholders. 2,638,150 qualified subordinated mandatory convertible bearer bonds ("Bonds") with a nominal value of EUR 3.00 each (ISIN: DE000A3E4548 / WKN: A3E454) were offered for subscription at a subscription or placement price of 100% of their nominal value, corresponding to EUR 3.00 each in cash. The subscription period ends on August 13, 2020.

    According to the current evaluation, all Bonds have been successfully placed - not considering the demand during the ongoing private placement.

    Forward Looking

    Leverkusen, Germany, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (GREY:BFFTF) announced on July 27, 2020 the issuance of the 1.00% qualified subordinated mandatory convertible bond 2020/2021 with pre-emptive subscription rights for shareholders. 2,638,150 qualified subordinated mandatory convertible bearer bonds ("Bonds") with a nominal value of EUR 3.00 each (ISIN: DE000A3E4548 / WKN: A3E454) were offered for subscription at a subscription or placement price of 100% of their nominal value, corresponding to EUR 3.00 each in cash. The subscription period ends on August 13, 2020.

    According to the current evaluation, all Bonds have been successfully placed - not considering the demand during the ongoing private placement.

    Forward Looking Statements:

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

    Contact: Biofrontera AG

    Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290

    E-mail:

    Primary Logo

    View Full Article Hide Full Article
  2. Leverkusen, Aug. 10, 2020 (GLOBE NEWSWIRE) -- The Executive Board of Biofrontera AG (GREY:BFFTF) has decided on 27 July 2020, with the approval of the Supervisory Board, to issue a 1.00 % qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E4548 / WKN: A3E454). It is divided into up to 2,638,150 qualified subordinated mandatory convertible bearer bonds ("Bonds") with a nominal value of EUR 3.00 each and a total nominal value of up to EUR 7,914,450. The shareholders or holders of subscription rights were invited by an announcement in the Federal Gazette (Bundesanzeiger) of 29 July 2020 to exercise their subscription rights to the Bonds during normal business hours in the period from 30 July 2020 up to 13 August 2020 (included…

    Leverkusen, Aug. 10, 2020 (GLOBE NEWSWIRE) -- The Executive Board of Biofrontera AG (GREY:BFFTF) has decided on 27 July 2020, with the approval of the Supervisory Board, to issue a 1.00 % qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E4548 / WKN: A3E454). It is divided into up to 2,638,150 qualified subordinated mandatory convertible bearer bonds ("Bonds") with a nominal value of EUR 3.00 each and a total nominal value of up to EUR 7,914,450. The shareholders or holders of subscription rights were invited by an announcement in the Federal Gazette (Bundesanzeiger) of 29 July 2020 to exercise their subscription rights to the Bonds during normal business hours in the period from 30 July 2020 up to 13 August 2020 (included) to avoid exclusion. It was also provided that the subscription price would be published in the Federal Gazette (Bundesanzeiger) and via an electronic information medium no later than three days before the end of the subscription period.

    The subscription price for each of the Bonds was set at

    100 % of their nominal value of EUR 3,00.

    Thus, the cash payment for each bond subscribed is EUR 3.00.

    The Management Board

    Forward Looking Statements:

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

    Contact: Biofrontera AG

    Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290

    E-mail:

    Primary Logo

    View Full Article Hide Full Article
  3. Leverkusen, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG ((NASDAQ ticker symbol: BFRA, GREY:BFFTF), today resolved, with the approval of the Supervisory Board, to issue a qualified subordinated mandatory convertible bond subject to the granting of statutory subscription rights.

    The qualified subordinated mandatory convertible bond will mature on December 20, 2021, bears interest at 1% p.a. and consists of up to 2,638,150 bonds with a principal amount of EUR 3.00 each and a total principal amount of up to EUR 7,914,450.

    In accordance with the terms and conditions of the convertible bonds, each of these convertible bonds can be converted into no-par ordinary registered shares of the company with a notional…

    Leverkusen, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG ((NASDAQ ticker symbol: BFRA, GREY:BFFTF), today resolved, with the approval of the Supervisory Board, to issue a qualified subordinated mandatory convertible bond subject to the granting of statutory subscription rights.

    The qualified subordinated mandatory convertible bond will mature on December 20, 2021, bears interest at 1% p.a. and consists of up to 2,638,150 bonds with a principal amount of EUR 3.00 each and a total principal amount of up to EUR 7,914,450.

    In accordance with the terms and conditions of the convertible bonds, each of these convertible bonds can be converted into no-par ordinary registered shares of the company with a notional interest in the share capital of EUR 1.00 per share and a right to dividends from the year of the share issue. The initial conversion price per share is EUR 3.00. The initial conversion ratio is 1 : 1.

    The bondholders are obliged to convert their bonds at the maturity date of the convertible bond. The company is entitled to convert the convertible bonds into shares at any time if a trigger price defined in the terms and conditions of the convertible bonds has been met.

    The shareholders are granted the preemptive right to the convertible bonds as an indirect subscription right via Quirin Privatbank AG, Berlin.

    The subscription price will be published in the Federal Gazette (Bundesanzeiger) and via an electronic publication no later than three days before the end of the subscription period. The subscription price will be based on the stock exchange price of the Company's shares (GREY:BFFTF) at the time the subscription price is determined and will not exceed 100% of the nominal value of the convertible bonds of EUR 3.00 each. The subscription price will be established based on the ratio of the stock exchange price of the shares of the Company to the nominal value of the convertible bonds as a percentage of the nominal value of the convertible bonds, whereby a discount of up to 10 % may be applied to the percentage determined by this method. Sections 199 (2) and 9 (1) AktG remain unaffected.

    For further details, please refer to the Subscription Offer, which is expected to be published on July 29, 2020 in the Federal Gazette.

    The company intends to use the expected net proceeds to fund clinical studies for label expansion of Ameluz®, to further finance sales and marketing efforts of Ameluz® in the USA and for working capital and general corporate purposes.

    The Management Board

    Forward Looking Statements:

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

    Contact: Biofrontera AG

    Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290

    E-mail:

    Primary Logo

    View Full Article Hide Full Article
  4. Leverkusen, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))), an international biopharmaceutical company, today announced that the appointments and service contracts of both members of the Management Board, CEO Prof. Dr. Hermann Lübbert and CFO Thomas Schaffer, have each been extended for an additional 2 year-term.

    "We are looking forward to continuing the excellent and fruitful cooperation with the Biofrontera Management Board. The coming months are crucial for the further development of Biofrontera into an independent, profitable specialty pharma company. The Supervisory Board expressly appreciates continuity in the management of Biofrontera AG during this…

    Leverkusen, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))), an international biopharmaceutical company, today announced that the appointments and service contracts of both members of the Management Board, CEO Prof. Dr. Hermann Lübbert and CFO Thomas Schaffer, have each been extended for an additional 2 year-term.

    "We are looking forward to continuing the excellent and fruitful cooperation with the Biofrontera Management Board. The coming months are crucial for the further development of Biofrontera into an independent, profitable specialty pharma company. The Supervisory Board expressly appreciates continuity in the management of Biofrontera AG during this very important strategic and operational phase of the company. I am very pleased that in both cases this has been achieved," commented the Chairman of the Supervisory Board, Dr. Ulrich Granzer. "Over the next two years, the Supervisory Board, together with the Management Board, will successively implement succession planning which has already been jointly initiated".

    The term of office and service contracts for both Prof. Dr. Hermann Lübbert and Thomas Schaffer will run until December 31, 2022.

    The allocation of responsibilities within the Management Board remains unchanged.

    -End-

    For enquiries, please contact:



    Biofrontera AG



    Thomas Schaffer, Chief Financial Officer
     



    +49 (0) 214 87 63 2 0



    IR UK: Seton Services



    Toni Vallen
     



    +44 (0) 207 229 0805

    About Biofrontera:

    Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

    The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.

    Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.

    Primary Logo

    View Full Article Hide Full Article
  5. Leverkusen, Germany, July 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company" or the "Biofrontera-Group"), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first six months of fiscal year 2020.

    Accordingly, the Biofrontera-Group generated total revenue of EUR 16.0 to 16.2 million in the period from January 1st to June 30th, 2020, which corresponds to an increase of about 16% compared to EUR 13.9 million in the same period last year. Total revenue includes a EUR 6.0 million up-front payment received from Maruho Co., Ltd. pursuant to the licensing agreement signed on April 20, 2020. During the reporting period, the Company generated revenue…

    Leverkusen, Germany, July 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company" or the "Biofrontera-Group"), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first six months of fiscal year 2020.

    Accordingly, the Biofrontera-Group generated total revenue of EUR 16.0 to 16.2 million in the period from January 1st to June 30th, 2020, which corresponds to an increase of about 16% compared to EUR 13.9 million in the same period last year. Total revenue includes a EUR 6.0 million up-front payment received from Maruho Co., Ltd. pursuant to the licensing agreement signed on April 20, 2020. During the reporting period, the Company generated revenue from product sales between EUR 9.5 to 9.7 million, a decrease of about 30% compared to the first half of 2019. Preliminary unaudited six-months sales revenue in the U.S. were between EUR 6.3 and 6.4 million, compared to EUR 10.2 million, a decrease of about 38%, in the same period in 2019. Product sales of Xepi™ contributed about EUR 0.1 million (previous year period: EUR 0.6 million from Xepi™ and AKTIPAK®). Revenue in Germany increased by about 10% to EUR 2.3 to 2.4 million in the first half of 2020 compared to EUR 2.2 million in the same period last year. In the remainder of Europe, product sales were between EUR 0.9 and 1.0 million compared to EUR 1.4 million in the prior-year period, a decrease of about 29%.

    Overall, sales in the first half of 2020, and especially in the second quarter, were strongly influenced by the impact of the global coronavirus crisis.

    The Company confirms its budget assumption for sales revenue for the 2020 financial year of EUR 34 to 38 million published on June 30, 2020.

    Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen

    ISIN: DE0006046113

    WKN: 604611

    Contact: Biofrontera AG

    Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290

    E-mail:

    Forward Looking Statements:

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

    Primary Logo

    View Full Article Hide Full Article
View All Biofrontera AG News